| Autor: |
Valzano F; Department of Medical Biotechnologies, University of Sienagrid.9024.f, Siena, Italy., Boncompagni SR; Department of Medical Biotechnologies, University of Sienagrid.9024.f, Siena, Italy., Micieli M; Department of Experimental and Clinical Medicine, University of Florencegrid.8404.8, Florence, Italy., Di Maggio T; Department of Medical Biotechnologies, University of Sienagrid.9024.f, Siena, Italy., Di Pilato V; Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy., Colombini L; Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Sienagrid.9024.f, Siena, Italy., Santoro F; Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Sienagrid.9024.f, Siena, Italy., Pozzi G; Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Sienagrid.9024.f, Siena, Italy., Rossolini GM; Department of Experimental and Clinical Medicine, University of Florencegrid.8404.8, Florence, Italy.; Clinical Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy., Pallecchi L; Department of Medical Biotechnologies, University of Sienagrid.9024.f, Siena, Italy. |
| Abstrakt: |
Chronic colonization by Pseudomonas aeruginosa is critical in cystic fibrosis (CF) and other chronic lung diseases, contributing to disease progression. Biofilm growth and a propensity to evolve multidrug resistance phenotypes drastically limit the available therapeutic options. In this perspective, there has been growing interest in evaluating combination therapies, especially for drugs that can be administered by nebulization, which allows high drug concentrations to be reached at the site of infections while limiting systemic toxicity. Here, we investigated the potential antibiofilm activity of N -acetylcysteine (NAC) alone and in combination with colistin against a panel of P. aeruginosa strains (most of which are from CF patients) and the transcriptomic response of a P. aeruginosa CF strain to NAC exposure. NAC alone (8,000 mg/L) showed a limited and strain-dependent antibiofilm activity. Nonetheless, a relevant antibiofilm synergism of NAC-colistin combinations (NAC at 8,000 mg/L plus colistin at 2 to 32 mg/L) was observed with all strains. Synergism was also confirmed with the artificial sputum medium model. RNA sequencing of NAC-exposed planktonic cultures revealed that NAC (8,000 mg/L) mainly induced (i) a Zn 2+ starvation response (known to induce attenuation of P. aeruginosa virulence), (ii) downregulation of genes of the denitrification apparatus, and (iii) downregulation of flagellar biosynthesis pathway. NAC-mediated inhibition of P. aeruginosa denitrification pathway and flagellum-mediated motility were confirmed experimentally. These findings suggested that NAC-colistin combinations might contribute to the management of biofilm-associated P. aeruginosa lung infections. NAC might also have a role in reducing P. aeruginosa virulence, which could be relevant in the very early stages of lung colonization. IMPORTANCE Pseudomonas aeruginosa biofilm-related chronic lung colonization contributes to cystic fibrosis (CF) disease progression. Colistin is often a last-resort antibiotic for the treatment of such P. aeruginosa infections, and it has been increasingly used in CF, especially by nebulization. N -acetylcysteine (NAC) is a mucolytic agent with antioxidant activity, commonly administered with antibiotics for the treatment of lower respiratory tract infections. Here, we show that NAC potentiated colistin activity against in vitro biofilms models of P. aeruginosa strains, with both drugs tested at the high concentrations achievable after nebulization. In addition, we report the first transcriptomic data on the P. aeruginosa response to NAC exposure. |
